Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease

@article{Labarthe2008MediumchainFA,
  title={Medium-chain Fatty Acids as Metabolic Therapy in Cardiac Disease},
  author={François Labarthe and Roselle G{\'e}linas and Christine Des Rosiers},
  journal={Cardiovascular Drugs and Therapy},
  year={2008},
  volume={22},
  pages={97-106}
}
IntroductionMedium-chain fatty acids (MCFAs) have physical and metabolic properties that are distinct from those of long-chain fatty acids, which make them a readily available cellular energy source. These properties have been used advantageously in the clinics for more than 50 years for treating lipid absorption disorders, undernourished patients, and more recently subjects with long-chain fatty acid oxidation defects. In these latter subjects, nutritional interventions with MCFA-containing… Expand
Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome.
TLDR
Experimental studies demonstrate that dietary MCFAs/MCTs suppress fat deposition through enhanced thermogenesis and fat oxidation in animal and human subjects and several reports suggest that MCF as well as MCTs offer the therapeutic advantage of preserving insulin sensitivity in animal models and patients with type 2 diabetes. Expand
Intake of medium-chain fatty acids induces myocardial oxidative stress and atrophy
TLDR
Excessive LAA consumption may damage the myocardium and the damage might result from oxidative stress accumulation and cellular atrophy. Expand
Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.
TLDR
This review will describe the mechanistic bases and rationale for the use of pharmacological agents that modify energy substrate metabolism to improve cardiac function in the ischemic and failing heart. Expand
Targeting mitochondrial oxidative metabolism as an approach to treat heart failure.
TLDR
While targeting mitochondrial oxidative metabolism is a promising strategy to treat heart failure, further studies are needed to confirm the potential beneficial effect of modulating these metabolic targets as an approach to treating heart failure. Expand
Ketone body metabolism and cardiovascular disease.
TLDR
Ketone bodies are metabolized through evolutionarily conserved pathways that support bioenergetic homeostasis, particularly in brain, heart, and skeletal muscle when carbohydrates are in short supply, and further investigation in disease models and in humans may ultimately yield tailored diagnostic strategies and therapies for specific pathological states. Expand
Alterations in carbohydrate metabolism and its regulation in PPARalpha null mouse hearts.
TLDR
The present study investigated potential alterations in the myocardial utilization of CHOs for energy production and anaplerosis in 12-wk-old peroxisome proliferator-activating receptor-alpha (PPARalpha) null mice to suggest potential mechanisms involved in this defective CHO metabolism. Expand
Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure
TLDR
It is suggested that myocardial FA uptake through CD36 is indispensable for sufficient ATP production and for preventing an increased glycolytic flux-mediated structural remodeling during pressure overload-induced hypertrophy. Expand
Myocardial substrate metabolism in heart disease.
TLDR
Whether a primary metabolic abnormality in myocardial fuel utilisation leads to cardiac dysfunction, or whether changes in substrate selection are a consequence of the disease state is important as the ability to manipulate cardiac substrate utilisation may offer a therapeutic opportunity for cardiac disease. Expand
Cardiac ketone body metabolism.
TLDR
Evidence indicates that increased ketone body metabolism is a feature of heart failure, and is accompanied by other changes in substrate selection, which offers the possibility of using exogenous ketones to treat the failing heart. Expand
Short- and medium-chain fatty acids in energy metabolism: the cellular perspective
TLDR
Short- and medium-chain fatty acids (SCFAs and MCFAs), independently of their cellular signaling functions, are important substrates of the energy metabolism and anabolic processes in mammals and provide reducing equivalents to the respiratory chain and partly decrease efficacy of oxidative ATP synthesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 82 REFERENCES
Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications.
TLDR
Differences in metabolic handling of MCFA versus LCFA are considered and it is concluded that MCFA hold potential as weight loss agents. Expand
Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity.
TLDR
From the literature reviewed, it is concluded that MCT increase energy expenditure, may result in faster satiety and facilitate weight control when included in the diet as a replacement for fats containing LCT. Expand
Implications of impaired ketogenesis in fatty acid oxidation disorders.
  • S. Olpin
  • Biology, Medicine
  • Prostaglandins, leukotrienes, and essential fatty acids
  • 2004
TLDR
Clinically patients usually present in infancy with acute life-threatening hypoketotic hypoglycaemia, liver disease, hyperammonaemia and cerebral oedema, with or without cardiac involvement, usually following a period of catabolic stress, and novel approaches to treatment include the use of d,l-3-hydoxybutyrate or heptanoate as an alternative energy source. Expand
Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.
TLDR
This treatment led rapidly to clinical improvement that included the permanent disappearance of chronic cardiomyopathy, rhabdomyolysis, and muscle weakness in three patients with very-long-chain acyl-CoA dehydrogenase deficiency and opens new avenues for the management of patients with mitochondrial fat oxidation disorders. Expand
Fatty acid oxidation disorders.
TLDR
The normal process of mitochondrial fatty acid beta-oxidation is addressed and the clinical, metabolic, and molecular aspects of more than 20 known inherited diseases of this pathway that have been described to date are discussed. Expand
Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: Role of sarcolemmal substrate transporters
TLDR
In this review, recent findings on the insulin and contraction signalling pathways involved in substrate uptake and utilization by cardiac myocytes under physiological conditions are discussed and a pivotal role for substrate transporters is suggested. Expand
Influence of dietary fatty acid chain-length on metabolic tolerance in mouse models of inherited defects in mitochondrial fatty acid beta-oxidation.
TLDR
The results indicate the important influences dietary fatty acids may have by providing enhanced metabolic tolerance in patients with inborn errors of fatty acid oxidation and demonstrate that there may be crucial variables involved in the treatment of these patients, including the patient's specific enzyme deficiency, the quantity and chain-length of dietary fat, which may provide positive effects. Expand
Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure
TLDR
It is proposed that both glucose and fatty acid oxidation are required for optimal function of the failing heart. Expand
High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction.
TLDR
Test the hypothesis that the progression of heart failure would be exacerbated by elevated myocardial lipids and an associated ceramide-induced inhibition of mitochondrial oxidative phosphorylation and ETC complex activities and did not adversely affect LV contractile function or remodeling, despite elevations in myocardia ceramide. Expand
Myocardial substrate metabolism in the normal and failing heart.
TLDR
This review discusses the metabolic changes that occur in chronic heart failure, with emphasis on the mechanisms that regulate the changes in the expression of metabolic genes and the function of metabolic pathways and the consequences of these metabolic changes on cardiac function. Expand
...
1
2
3
4
5
...